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Abstract
Transforming growth factor b (TGF-b) induces the process of epithelial-mesenchymal transition (EMT) through the Smad
and JNK signaling. However, it is unclear how these pathways interact in the TGF-b1-induced EMT in rat peritoneal
mesothelial cells (RPMCs). Here, we show that inhibition of JNK activation by introducing the dominant-negative JNK1 gene
attenuates the TGF-b1-down-regulated E-cadherin expression, and TGF-b1-up-regulated a-SMA, Collagen I, and PAI-1
expression, leading to the inhibition of EMT in primarily cultured RPMCs. Furthermore, TGF-b1 induces a bimodal JNK
activation with peaks at 10 minutes and 12 hours post treatment in RPMCs. In addition, the inhibition of Smad3 activation
by introducing a Smad3 mutant mitigates the TGF-b1-induced second wave, but not the first wave, of JNK1 activation in
RPMCs. Moreover, the inhibition of JNK1 activation prevents the TGF-b1-induced Smad3 activation and nuclear
translocation, and inhibition of the TGF-b1-induced second wave of JNK activation greatly reduced TGF-b1-induced EMT in
RPMCs. These data indicate a crosstalk between the JNK1 and Samd3 pathways during the TGF-b1-induced EMT and fibrotic
process in RPMCs. Therefore, our findings may provide new insights into understanding the regulation of the TGF-b1-
related JNK and Smad signaling in the development of fibrosis.
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Introduction
Peritoneal fibrosis, a major complication of peritoneal dialysis,
largely limits the effectiveness of peritoneal dialysis as a long-term
renal replacement therapy [1]. Peritoneal fibrosis is attributed to
the epithelial-mesenchymal transition (EMT) of peritoneal meso-
thelial cells [2], leading to the formation of submesothelial
myofibroblasts associated with the accumulation of extracellular
matrix (ECM) [3]. During the process of EMT, epithelial cells
usually lose their adhesion ability because of the down-regulation
of E-cadherin and b-catenin expression and the cytoskeletal
rearrangement, resulting in up-regulated a-SMA expression and
actin reorganization. This process further promotes the disruption
of the basement membrane, and enhances cell migration and
invasion [4,5]. Increasing evidence indicates that transforming
growth factor-b (TGF-b) can initiate the EMT process in
peritoneal mesothelial cells, and is a key mediator of the dialysis-
related peritoneal fibrosis [6,7]. However, the mechanisms that
regulate the TGF-b-induced EMT in peritoneal mesothelial cells
are not fully understood.
The TGF-b/Smad signaling is critical for regulating the cell-
state specific modulation. TGF-b binds to the type II receptor,
which recruits and activates the type I receptor, leading to the
downstream Smad2/3 phosphorylation and nuclear translocation
and regulating the expression of target genes [8]. Previous studies
have shown that the JNK/MAPK pathway regulates the TGF-
b1-induced and Smad2-dependent IL-6 production in human
bronchial epithelial cells [9] and modulates the TGF-b-induced
transcriptional responses [10]. Many studies have suggested that
the JNK signal pathway contributes to the fibrotic process in
different models of diseases [11,12]. Apparently, there is a mutual
interaction between the TGF-b-related JNK and Smad pathways
[13–16]. Our previous studies have demonstrated that the
aberrant activation of the TGF-b/Smad signaling is associated
with the peritoneal dialysis fluid-increased fibrotic peritoneum
thickness, a-smooth muscle actin (a-SMA), collagen I, and
plasminogen activator inhibitor-1 (PAI-1) expression, leading to
the development of peritoneal fibrosis in rats [17,18]. Our recent
study has demonstrated that TGF-b1 induces the JNK and
Smad3 activation and EMT in rat peritoneal mesothelial cells
(RPMCs) [19]. However, the role of the JNK1 signal pathway in
the TGF-b1-induced EMT and the interaction between the
JNK1 and Smad3 pathways in RPMCs remain poorly under-
stood.
In the present study, we examined the impact of inducing
dominant-negative JNK1 expression on the TGF-b1–induced
Smad3 activation and EMT in RPMCs, and determined the effect
of inducing mutant Smad3 expression on the TGF-b1-induced
JNK activation in RPMCs.
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JNK1 mediates the TGF-b1-induced EMT of RPMCs
To analyze whether JNK1 could modulate the TGF-b1-
induced EMT, RPMCs were infected with Ad-DN-JNK1
(Recombinant adenovirus vectors that expressed a dominant-
negative JNK1) or Ad-control (control recombinant adenovirus),
and treated with, or without, TGF-b1 for 48 hours. The cell
morphology and the EMT-related myofibroblastic conversion
were characterized by histology and immunofluorescency. As
shown in Figure 1A, infection with Ad-DN-JNK1 alone did not
modulate RPMC morphology, as epithelial cell morphology with a
cobblestone-like growth pattern was observed in the Ad-control
and Ad-DN-JNK1-infected cells in the absence of TGF-b1
treatment (Figure 1A, a and b). Following treatment with TGF-
b1, many mesothelial cells that had been infected with Ad-control
became spindle fibroblast-like cells (Figure 1A, c), indicative of
myofibroblastic conversion. In contrast, RPMCs that had been
infected with Ad-DN-JNK1 remained epithelial cell morphology,
indicating that JNK1 is crucial for the TGF-b1–induced
myofibroblastic conversion in RPMCs (Figure 1A, d). Confocal
immunofluorescence analysis revealed that treatment with TGF-
b1 reduced E-cadherin expression and disrupted the cell-cell
interactions (Figure 1B, c), as compared with unstimulated
control cells (Figure 1B, a). Furthermore, although infection with
Ad-DN-JNK1 did not affect E-cadherin expression in the absence
of TGF-b1 (Figure 1B, b), infection with Ad-DN-JNK1 resulted
in a resistance of RPMCs to the TGF-b1-induced redistribution
of E-cadherin (Figure 1B, d). In addition, treatment of RPMCs
with TGF-b1 induced a remarkable reorganization of the
microfilament network and induced stress fiber formation,
determined by anti-a-SMA staining (Figure 1C, c). In contrast,
only little stress fiber formation was detected in the TGF-b1-
treated and Ad-DN-JNK1-infected RPMCs (Figure 1C, d), but
not in the TGF-b1-untreated cells (Figure 1C, a and b).
Moreover, treatment with TGF-b1 enhanced Collagen I
expression in RPMCs (Figure 1D, c), but not in the Ad-DN-
JNK1-infected cells (Figure 1D, d), as compared with that in the
control cells (Figure 1D, a and b).
Analysis of the relative levels of endogenous PAI-1 transcripts
revealed that treatment with TGF-b1 for 24 hours significantly
elevated the relative levels of PAI-1 mRNA transcripts, as
compared with that in the TGF-b1-untreated cells (Figure 1E
and F). However, the inducing effect of TGF-b1 on the PAI-1
transcription was mitigated by infection with Ad-DN-JNK1 in
RPMCs. Similar patterns of PAI-1 protein expression were
detected in different groups of cells (Figure 1G and H).
Collectively, these data indicate that TGF-b1 stimulates EMT
and that JNK1 activity is crucial for the TGF-b1-induced EMT in
primary cultured RPMCs.
TGF-b1 stimulates bimodal JNK activation with rapid,
transient, and gradual sustained peaks of activity
Our previous study has demonstrated that JNK can be activated
by TGF-b1 and that the highest activity of JNK occurs at
10 minutes post treatment in RPMCs [19]. However, it has also
been reported that TGF-b1 may induce bimodal JNK activation
in mink lung epithelial cells [14]. To determine the kinetics of the
TGF-b1-induced JNK activation, RPMCs were treated with
TGF-b1 and the levels of JNK1 and JNK2 phosphorylation were
characterized longitudinally by Western blot assays. As shown in
Figure 2, although the levels of JNK1 and JNK2 expression were
similar throughout the time course, the levels of phosphorylated
JNK1 and JNK2 appeared to be higher at 5–10 minutes and 12–
16 hours post TGF-b1 treatment. The relative ratios of phos-
phorylated JNK to JNK at 5–10 minutes and 12–16 hours post
treatment were significantly greater than that of the other time
points. Therefore, TGF-b1 induces two phases of JNK activation
in RPMCs in vitro.
TGF-b1-induced secondary peak of JNK1/2 activation,
but not the first JNK1/2 activation, is mediated by Smad3
signaling
To test how the Smad3 affects the TGF-b1-induced JNK1/2
activation, RPMCs were transfected with vehicle pcDNA3 or
pcDNA3-Smad3M carrying mutations at the C-terminus phos-
phorylation sites (ser422/425) of the Smad3, and then treated
with, or without, TGF-b1 for 10 minutes or 12 hours, respectively.
The relative levels of JNK1 and JNK 2 phosphorylation in those
cells were determined by Western blot assays (Figure 3). There was
no significant difference in the relative levels of phosphorylated
JNK1 and JNK2 in the vehicle and pcDNA3-Smad3M-transfected
cells at 10 minutes post TGF-b1 treatment (Figure 3A–C). In
contrast, the relative levels of phosphorylated JNK1 and JNK2 in
the pcDNA3-Smad3M-transfected cells were significantly lower
than that of the controls at 12 hours post TGF-b1 treatment
(Figure 3D–F). These data suggest that the Smad3 is important for
TGF-b1 to induce the second peak of JNK activation, but not the
first peak of JNK activation, in RPMCs in our experimental
system.
JNK1 regulates the TGF-b1-stimulated Smad3
phosphorylation and nuclear translocation
To dissect the role of JNK1 in the TGF-b1-induced Smad3
activation, RPMCs were infected with Ad-DN-JNK1 or Ad-
control, and then treated with, or without, TGF-b1 for
30 minutes, respectively. The relative levels of phosphorylated
Smad3 were determined by Western blot assays (Figure 4).
Infection with Ad-control did not modulate the Smad3 expression
and phosphorylation (Figure 4A and B). Treatment with TGF-b1
significantly elevated the relative levels of phosphorylated Smad3
in the vehicle-infected cells, but not in the Ad-DN-JNK1 infected
cells. Furthermore, TGF-b1 effectively induced the p-Smad3
nuclear translocation in the Ad-control-infected cells, but not in
the Ad-DN-JNK1-infected cells because strong staining of FITC-
anti-p-Smad3 was observed predominately in the nuclei of Ad-
control-infected RPMCs (Figure 4C). Together, these data suggest
that JNK1 regulates the TGF-b1-induced Smad3 phosphorylation
and nuclear translocation in RPMCs in vitro.
Blockade of the second wave of TGF-b1-induced JNK
activation mitigates the TGF-b1-induced EMT in RPMCs
To determine whether the second wave of TGF-b1-induced
JNK activation is involved in the TGF-b1-induced EMT in
RPMCs, we stimulated RPMCs with TGF-b1 for eight hours and
then treated with 10 mM SP600125, a specific JNK inhibitor,
followed by characterizing the JNK phosphorylation at 12 hours
and EMT in RPMCs at 48 hours post TGF-b1 treatment. We
found that treatment with SP600125 effectively inhibited TGF-
b1-induced JNK1/2 phosphorylation at 12 hours post TGF-b1
treatment (Figure 5 A and B) and significantly mitigated the
TGF-b1-down-regulated E-cadherin expression and TGF-b1-
enhanced a-SMA and Collagen I expression in RPMCs (Figure 5
C and D). Apparently, the second wave of JNK activation
induced by TGF-b1 is important for TGF-b1-induced EMT in
RPMCs.
Crosstalk between Smad and JNK Signaling
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32009Figure 1. The JNK1 regulates the TGF-b1-induced EMT process in RPMCs. RPMCs were infected with Ad-DN-JNK1 or Ad-control for 24 h, and
stimulated with, or without, 10 ng/ml of TGF-b1 for 24 or 48 hours, respectively. Their morphologies, E-cadherin, a-SMA, Collagen I, and PAI-1
expression were determined by histology, immunofluorescence, RT-PCR, and Western blot assays, respectively. (A) Photomicrographs of confluent
monolayer of RPMCs (magnification6200). (B–D) Immunofluorescence analyses of E-cadherin (B), a-SMA (C) and Collagen I (D). After stimulating with
TGF-b1 for 48 hours, the cells were fixed with 4% paraformaldehyde, and stained with the specific FITC-conjugated antibodies, followed by
counterstaining of the nucleus with DAPI (magnification 6400). (E) RT-PCR analysis of the PAI-1 and GAPDH mRNA transcripts. (F) Quantitative
analysis of the relative levels of PAI-1 mRNA transcripts to control GAPDH by densitometric scanning. (G) Western blot analysis of the PAI-1 protein.
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In the present study, we examined the roles of the JNK1
pathway in the TGF-b1-induced EMT and explored the crosstalk
between the JNK1 and Smad3 pathways in RPMCs. Our results
indicated that JNK1 positively regulated the TGF-b1-down-
regulated E-cadherin expression and up-regulated a-SMA,
collagen I, and PAI-1 expression as well as myofibroblastic
conversion in RPMCs. Furthermore, we found that TGF-b1
induced the JNK activation in a bimodal manner and that the
TGF-b1-induced second peak, but not the first peak, of JNK
activation appeared to be supported by Smad3 in RPMCs.
Moreover, we found that JNK1 was critical for the TGF-b1-
induced Smad3 phosphorylation and nuclear translocation in
RPMCs. These data extended previous findings and suggested a
mutual interaction between the TGF-b1-related JNK1 and Smad3
signal pathways during the EMT process in RPMCs.
Following the process of EMT, epithelial cells usually lose their
adhesion ability because of the down-regulation of E-cadherin and
b-catenin expression, cytoskeletal rearrangement, up-regulated a-
SMA expression, and actin reorganization. The EMT of
peritoneal mesothelial cells contributes to the development of
peritoneal fibrosis [2,20]. The EMT process is regulated by the
TGF-b/Smad signaling and the MAPK/JNK signaling. Our
previous study and those of others have demonstrated that
inhibition of JNK activation effectively mitigates the TGF-b1–
upregulated a-SMA, connective tissue growth factor (CTGF), and
Collagen I expression, and down-regulated E-cadherin expression
as well as the EMT process in different cell models [19,21–23]. In
the present study, we found that inhibition of JNK1 activity
effectively attenuated the TGF-b1-down-regulated E-cadherin
expression, but up-regulated a-SMA, Collagen I, and PAI-1
expression in RPMCs. Therefore, the JNK1 regulates the TGF-
b1-induced EMT in primary cultures of RPMCs. Actually, the
JNK1 has been shown to regulate the TGF-b1-stimulated
fibronectin expression and EMT in human fibrosarcoma derived
cells and mouse tracheal epithelial cells [24,25], and the TGF-b1–
induced expression of profibrotic genes in vivo [12]. Apparently,
the JNK1 is a critical regulator of the process of EMT. We are
interested in investigating the role of the JNK2 in the process of
EMT during the development of peritoneal fibrosis.
PAI-1 is one of the major targets regulated by the TGF-b signal
pathway [26] and has been thought to regulate the ECM turnover
by preventing plasmin generation and plasmin-mediated MMP
activation [27]. Up-regulated PAI-1 expression is associated with
the development of peritoneal fibrosis [28], and the TGF-b1-
stimulated PAI-1 expression is regulated by the JNK1 [24]. We
found that inhibition of JNK1 mitigated the TGF-b1-stimulated
PAI-1 expression in RPMCs, consistent with a previous observa-
tion that knockdown of JNK1 expression diminished the TGF-b1-
induced PAI-1 expression in epithelial cells [25]. Notably, previous
studies have shown that the JNK upstream and other MAPK
signal events, such as MEKK-1, ERK, and p38MAPK, are crucial
regulators of the TGF-b1-stimulated PAI-1 expression in different
types of epithelial and mesangial cells [15,29–31]. It is possible that
blockage of MEKK1 activation minimizes the JNK activation,
leading to inhibition of the TGF-b1-stimulated PAI-1 expression.
Given that inhibition of JNK1 activation attenuated the Smad3
activation, the JNK1 may be a major regulator of the TGF-b1-
stimulated PAI-1 expression in RPMCs.
The expression and deposition of ECM and Collagen I are
important for the development of peritoneal fibrosis. The
expression of Collagen I is positively regulated by the JNK
activation. We found that inhibition of JNK1 activation mitigated
the TGF-b1-stimulated Collagen I expression in RPMCs. Our
data are consistent with previous findings that treatment with an
inhibitor of the JNK activation prevented the TGF-b1-stimualted
Collagen I expression [19,32]. However, our data argued against
the findings that the ERK pathway, but not the JNK pathway, is
critical for regulating the TGF-b1-mediated collagen I expression
in human mesangial cells [33] and that knockdown of JNK1 does
not affect the TGF-b1-induced collagen I expression in pulmonary
fibroblasts [34]. In addition, inhibition of the p38MAPK
activation reduces the TGF-b1-mediated collagen I expression in
hepatic stellate cells [35]. These disparate results suggest that
different MAPK pathways regulate the TGF-b-stimulated ECM-
related gene expression in different types of cells.
Many studies have shown that TGF-b1 can induce the JNK
activation. However, the pattern of the TGF-b1-induced JNK
activation remains in debate. While majority of studies indicates
that TGF-b1 induces a rapid JNK activation, peaking at 10–
30 minutes, and declining 1 hour post treatment [19,22,29,36,37],
another study reveals that TGF-b1 induces a bimodal JNK
activation in mink lung epithelial cells [14]. We determined the
kinetics of TGF-b1-induced JNK activation and found that the
first wave of JNK activation induced by TGF-b1 occurred as
described previously [19]. However, TGF-b1 induced a second
wave of JNK activation between 12–16 hours post treatment. Atfi
The cell lysates from different groups of cells that had been stimulated with TGF-b1 for 48 hours were subjected to Western blot analysis using the
specific antibodies against PAI-1 and GAPDH. (H) Quantitative analysis of the relative levels of PAI-1 protein to control GAPDH by densitometric
scanning. Data are expressed as representative images or as mean 6 SEM of each group of cells from at least three separate experiments. * P,0.05,
# P,0.01.
doi:10.1371/journal.pone.0032009.g001
Figure 2. TGF-b1 stimulates a bimodal JNK activation in
RPMCS. RPMCs were stimulated with 10 ng/ml of TGF-b1 in FBS-free
DMEM/F12, and the cells were harvested at the indicated time points.
The relative levels of JNK1, JNK2, phosphorylated JNK1 and JNK2 were
determined by Western blot assays using the specific antibodies. (A)
Western blot analysis of JNK1, JNK2, phosphorylated JNK1 and JNK2. (B)
Quantitative analysis. The relative ratios of phosphorylated JNK to JNK
were determined by densitometric scanning. Data are expressed as
representative images or as mean 6 SEM from at least three separate
experiments. * P,0.05 vs. the value at 0 time point.
doi:10.1371/journal.pone.0032009.g002
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JNK activation, with maximal activation at 12 hours, but not a
rapid wave of JNK activation. On the contrary, another study
suggests that TGF-b1 fails to induce the JNK activation in vitro
[39]. The difference may stem from varying types of cells and
diverse experimental conditions. More importantly, we found that
inhibition of the second wave of JNK activation mitigated the
TGF-b1-down-regulated E-cadherin, and enhanced a-SMA and
Collagen I expression in RPMCs. These data further indicated the
importance of JNK in regulating TGF-b1-induced EMT. These
findings are supported by a recent report that knockdown of JNK
expression inhibits the TGF-b1-induced CTGF and collagen I
expression in telomerase-immortalized human cornea stroma
fibroblast cells [40]. However, inhibition of the second wave of
JNK activation failed to completely diminish TGF-b1-induced
EMT in RPMCs, suggesting that other pathways may also
contribute to the pathogenesis of EMT [41].
Our previous studies have demonstrated that the TGF-b/Smad
pathway plays a crucial role in the development of peritoneal
dialysis fluid-induced peritoneal fibrosis in rats [17,18]. The
Smad3 is a signal transducer, and the Smad3-deficient mice are
resistant to the TGF-b1-induced peritoneal fibrosis [42]. Given
that TGF-b1 activates both the Smad3 and JNK pathways, we
examined the potential interaction between these pathways in the
TGF-b1-induced EMT process in RPMCs. We found that
inhibition of the Smad3 activation by introducing a mutant
Smad3M significantly mitigated the TGF-b1-induced JNK
activation at 12 hours, but not 10 minutes, post treatment,
consistent with previous studies in other cells [14,43]. These data
reveal for the first time that, in primary cultures of RPMCs,
Smad3 signaling reinforces the JNK pathway by augmenting the
second wave of JNK activation induced by TGF-b1. The failure of
Smad3 to regulate the TGF-b1-induced early JNK activation
likely stems from the fact that TGF-b1 induces the Smad3 peak
activation at 30 minutes post treatment [19]. Furthermore, we
found that inhibition of the JNK1 activation dramatically reduced
the TGF-b1-induced Smad3 activation and almost abolished
Smad3 nuclear translocation in RPMCs. In addition, inhibition of
the second wave of JNK1 activation induced by TGF-b1
dramatically mitigated the TGF-b1-induced EMT in RPMCs.
Apparently, TGF-b1 induces Smad3 activation and the first wave
of JNK1 activation. The activated JNK1 enhances the TGF-b1-
related Smad3 activation and nuclear translocation, which in turn
enhances the second wave of JNK activation, leading to a cascade
Figure 3. The Smad3 regulates the TGF-b1-induced second wave, but not the first wave, of JNK activation. RPMCs were transiently
transfected with the pcDNA3-SamdM or empty vector pcDNA3 for 24 hours and treated with, or without, 10 ng/ml of TGF-b1 for 10 minutes or
12 hours, respectively. The relative levels of JNK1, JNK2, phosphorylated JNK1 and JNK2 were determined by Western blot assays. (A) Western blot
analysis of the JNK activation at 10 minutes post TGF-b1 treatment. (B–C) Quantitative analysis. The relative levels of P-JNK1 to JNK1 (B) and p-JNK2 to
JNK2 (C) were determined by densitometric scanning. (D) Western blot analysis of the JNK activation at 12 hours post TGF-b1 treatment. (E–F)
Quantitative analysis. The relative levels of P-JNK1 to JNK1 (E) and p-JNK2 to JNK2 (F) were determined by densitometric scanning. Data are expressed
as representative images or as mean 6 SEM of at least three separate experiments. * P,0.05, NS: Not significant.
doi:10.1371/journal.pone.0032009.g003
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expression in RPMCs (Figure 6). The crosstalk between the TGF-
b1-induced JNK and Samd3 pathways are supported by previous
findings [34,44,45]. Notably, a previous study has shown that the
JNK-dependent Jun activation inhibits TGF-b-Smad3 activation
and downstream signaling [46] and that the JNK can act as a
repressor of the TGF-b-mediated biological responses [47].
Indeed, we found that inhibition of the JNK1 activation only
partially, but did not completely block the TGF-b1-induced
Samd3 signaling in RPMCs. It is possible that other undescribed
signal pathways regulate the TGF-b1-induced Samd3 signaling.
Together, the present findings indicate a crosstalk between the
Smad and JNK pathways during the TGF-b1-induced EMT and
fibrotic process in RPMCs.
In summary, our data indicate that the JNK1 is a crucial
amplifier of TGF-b1 signaling in promoting EMT in RPMCs.
Furthermore, our data demonstrated a crosstalk between the JNK
and Smad3 pathways during the TGF-b1-induced EMT and
fibrotic process in RPMCs. Therefore, our findings may provide
new insights into understanding the regulation of the TGF-b1-
medaited signaling during the process of EMT and fibrosis in
RPMCs.
Methods
Antibodies and Reagents
Human recombinant TGF-b1w a sf r o mR & DS y s t e m s
(Minneapolis, MN, USA); antibodies against p-JNK (Thr183/
Tyr185), JNK, p-Smad3 (Ser423/425)/Smad1 (Ser463/465),
GAPDH, and control IgG were purchased from Cell Signaling
(Beverly, MA, USA). Additional antibodies against Smad3 and
E-cadherin were from Upstate (Lake Placid, NY, USA) and BD
Biosciences (San Jose, CA, USA), respectively. Antibodies
against PAI-1 and Type I Collagen were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and Southern Biotech
(Birmingham, AL, USA), respectively. Monoclonal antibody
against smooth muscle actin was from Sigma (St. Louis,
Missouri, USA). Horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG, donkey anti-rabbit IgG, Alexa Fluro 546-
conjugated goat anti-rabbit IgG, Alexa Fluro 488-conjugated
goat anti-mouse IgG, and Alexa Fluor 546-conjugated donkey
anti-goat IgG were purchased from Cell Signaling. 4, 6-
diamidino-2-phenylindole (DAPI) was purchased from Molecu-
lar Probes (Leiden, The Netherlands). SP600125 (a JNK
inhibitor) was from Calbiochem (San Diego, CA, USA).
Dulbecco’s modified Eagle’s medium (DMEM)/F12 and Fetal
Bovine Serum (FBS) were purchased from Gibco-BRL (Grand
Island, NY, USA). The RT-PCR kit and TRIZOL reagent were
purchased from Invitrogen (San Diego, CA, USA).
RPMCs isolation and culture
RPMCs were isolated and cultured as described previously [19].
Briefly, male Sprague-Dawley (SD) rats at 150–250 g were
purchased from the Animal Experimental Center of Sun Yat-sen
University, Guangzhou, Guangdong, China. Individual rats were
injected intraperitoneally with 25–40 ml of 0.25% trypsinase-
0.02% EDTA-Na2, and two hours later, the abdominal fluid of
individual rats was collected, followed by centrifuging at 1516 g
for 10 minutes. The cells were cultured in 15% (v/v) FBS
DMEM/F12 medium in 25 cm
2 tissue culture flasks at 37uCi na
humidified 5% CO2 atmosphere. The cells were passaged every 3–
5 days, and RPMCs from the second and third passages at 80%
confluence were used for the following experiments. The
experimental protocols were approved by the Animal Care and
Use Committee of the Sun Yat-Sen University. The approval ID
for the animals used in this study is SCXK (Guangdong) 2006-
0015.
Figure 4. The JNK1 regulates the TGF-b1-induced Smad3 activation and nuclear translocation. RPMCs were infected with Ad-DN-JNK1 or
Ad-control for 24 hours and treated with, or without, 10 ng/ml of TGF-b1 for 30 minutes. The relative levels of Smad3 and phosphorylated Smad3
and the nucleus p-Smad3 were characterized by Western blot and immunofluorescence using FITC-anti-p-Smad3 and DAPI for counterstaining of the
nuclei. (A) Western blot analysis. (B) Quantitative analysis. The relative levels of phosphorylated Smad3 to Smad3 were determined by densitometric
scanning. Data are expressed as representative images or as mean 6 SEM of at least three separate experiments. * P,0.05,
# P,0.01. (C)
Immunofluorescence analyses of p-Smad3. The cells were fixed with 4% paraformaldehyde, and stained with FITC-anti-p-Smad3, followed by
counterstained with DAPI for the nuclei. The monolayers were visualized and imaged with a laser scanning confocal microscope (p-Smad3: green,
nucleus: red).
doi:10.1371/journal.pone.0032009.g004
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Rat wild-type Smad3 plasmid (pcDNA3.0-Myc-Smad3) was
generously provided by Prof. Huiyao Lan (University of Hongkong,
Hong Kong, China). The Smad3M carrying mutations at the C-
terminus phosphorylation sites (ser422/425) was generated by
polymerase chain reaction–based mutagenesis using primers of
forward59-TGGGTACCATGGAGCAAAAGCTAATAT-39,a n d
reverse 59-GCACTCGAGCTAACAGCGGATGCTTGGGGA-
39, and subcloned into pcDNA3.0, followed by sequencing. PCR
amplifications were performed at 95uC for 5 minutes and then 35
cycles of 94uC for 30 seconds, 53uC for 30 seconds, and 72uC for
45 seconds. RPMCs at 3610
5 cell/well were cultured overnight in
6-well plates, transfected in duplicate with 1 mg/well of pcDNA3.0-
Smad3M or control pcDNA3.0 using Lipofectamine 2000 (Invitro-
gen) for 24 hours, and the cells were stimulated with TGF-b1
(10 ng/ml) for 10 minutes or 12 hours, respectively.
Virus infection
Recombinant adenovirus vector (Ad-DN-JNK1) expressing
dominant-negative JNK1 was a gift from Dr. Borkan (Boston
University, Boston, Massachusetts, USA). RPMCs at 2610
5/well
were cultured overnight in 6-well plates and infected in duplicate
with 2610
7 PFU of Ad-DN-JNK1 or Ad-control for 24 hours, and
weresubjectedtoothertreatments asindicated inthefigure legends.
RNA isolation and RT-PCR
Total RNAwasextractedfrom RPMCs using the TRIZOL kit as
described previously [19], and reversely transcribed into cDNA
using the first-strand synthesis kit (Invitrogen). PCR amplifications
of specific DNA fragments were performed in duplicate with
TaqDNA polymerase and specific primers. The sequences of
primers were designed based on published GenBank sequences and
sense 59-TACGACATCCTGGAACTGCC-39, antisense 59-GGA-
GGAAGACGCCACTGT-39 for rat PAI-1; sense 59-GGCAA-
GTTCAATGGCACAGT-39, and antisense 59-AAGGTGGAG-
GAATGGGAGTT-39 for GAPDH. PCR amplifications were
performed at 94uC for 5 minutes, and then 30 and 29 cycles of
94uC for 30 seconds, 56uC for 30 seconds, and 72uC for
45 seconds, followed by extension at 72uC for 10 minutes for
PAI-1 and GAPDH, respectively. The PCR products were resolved
electrophoretically on 1.2% agarose gels containing 0.05 mg/ml of
ethidium bromide, and imaged using an Alpha Fluorchem TM
8900 auto-image system (Alpha Innotech, San Leandro, USA).
Western blot analysis
Different groups of RPMCs were lyzed in lysis buffer (Cell
Signaling), and after centrifuging, the cell lysates proteins were
determined by the Bradford protein assay (Bio-Rad, Hercules, CA,
USA). The cell lysates proteins (30–50 mg/lane) were separated by
Figure 5. The second wave of JNK activation is crucial for the TGF-b1-induced EMT in RPMCs. RPMCs were stimulated with, or without,
10 ng/ml of TGF-b1 for 8 hours and treated with, or without, 10 mM SP600125 (a specific inhibitor of JNK). The cells were harvested at 12 hours (A, B)
or 48 hours (C, D) post TGF-b1 stimulation. The relative levels of phosphorylated JNK1/2, and JNK1/2, E-cadherin, a-SMA, and Collagen I expression
were determined by Western blot assays and densitometric scanning. (A) Western blot analysis of JNK1/2 and phosphorylated JNK1/2. (B)
Quantitative analysis of the relative levels of phosphorylated JNK1/2 to JNK1/2. (C) Western blot analysis of E-cadherin, a-SMA, and Collagen I
proteins. (D) Quantitative analysis of the relative levels of E-cadherin, a-SMA, and Collagen I proteins to control GAPDH. Data are expressed as
representative images or as mean 6 SEM of each group of cells from at least three separate experiments. * P,0.05,
# P,0.01.
doi:10.1371/journal.pone.0032009.g005
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After blocking with 5% fat-free dried milk in TBST, the
membranes were incubated overnight at 4uC with anti-PAI-1,
anti-p-JNK, anti-JNK, anti-p-Smad3, anti-Smad3, anti-E-cad-
herin, anti-a-SMA, anti-Collagen I, anti-GAPDH, or 5 mg/ml of
control IgG, respectively. The bound antibodies were detected by
appropriate HRP-conjugated IgG and visualized using an
enhanced chemiluminescence system (Kodak, Rochester, NY,
USA). The relative levels of each protein to control GAPDH were
determined by densitometric analysis.
Immunofluorescence study
RPMCs at 2610
5/well were cultured overnight on glass cover-
slips in 3.5 cm-diameter tissue culture plates. The cells were
starved in serum-free medium for 15 hours and infected with
2610
7 PFU of Ad-DN-JNK1 or Ad-control for 24 hours in 0.2%
FBS DMEM/F12, respectively. The cells were treated in duplicate
with 10 ng/ml of TGF-b1 for 30 minutes (to detect phospho-
smad3) or 48 hours (to detect E-cadherin, a-SMA, and Collagen
I), fixed with 4% paraformaldehyde, and permeabilized in 0.1%
Triton X-100 for 10 minutes at room temperature, followed by
blocking with 5% BSA in PBS. Subsequently, the cells were
probed with polyclonal rabbit anti-phospho-smad3 (1:50), mono-
clonal mouse anti-E-cadherin (1:100), anti-a-SMA (1:100), poly-
clonal goat anti-Collagen I (1:100), or control IgG at 4uC
overnight, respectively. After washing, the bound antibodies were
detected with Alexa Fluro 488-conjugated anti-mouse IgG
(1:1000), Alexa Fluro 546-conjugated anti-rabbit IgG (1:1000),
or Alexa Fluor 546-conjugated anti-goat IgG, respectively. The
antibody staining was visualized and imaged under a laser
scanning confocal microscope (Zeiss LSM510, Oberkochen,
Germany).
Statistical analysis
Data are expressed as mean 6 SEM. The differences among
groups were assessed by ANOVA. When the F statistic was
significant, the mean values obtained from each group were then
compared by Fisher least significant difference method. A P value
,0.05 was considered statistically significant. The statistical
analysis was performed using SPSS for Windows 13.0.
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